Countries covered: Lebanon
The Lebanese pharmaceutical market has shown solid growth in recent years, with annual expansion of 6-7%, although this positive trend has been interrupted by the recent conflict. Particularly damaging has been the Israeli blockade, considering that Lebanon is reliant on imports for around 95% of pharmaceutical consumption.
BMI forecasts that the Lebanese drug market will be worth US$612.5mn at retail prices by 2010. Per-capita drug expenditure is expected to reach US$154.4 in 2010. Public-sector health expenditure is expected to remain almost unchanged at 30% of the total expenditure in healthcare. Drug prices in the country remain relatively high by regional standards. However, the government is said to be considering implementing a new pricing system, which would be based on the reference prices of drugs in similar markets around the world. This is unlikely to encourage multinational sector investment, but will enhance public access to medicines. Only about 62% of Lebanese have health insurance - either public or private - to help cover their drug costs.
Prescription drugs dominate the market, with OTC drugs accounting for approximately 10% of the market. Generic drugs take only a small market share due to a lack of awareness of their merits among both consumers and health professionals.
BMI's adjusted Business Environment Rankings for the Middle East reveal that Lebanon is in 11th place, ahead only of Iran, Nigeria and Zimbabwe. This is primarily due to a number of regulatory barriers such as lax intellectual property (IP) standards. Lebanon's uncertain long term political and economic climate also has a negative impact on our survey.
In the future, Lebanon will have to tighten its intellectual
property (IP) regime if it wishes to attract greater foreign
direct investment (FDI), and help its local industry to develop.
Currently, the IP regime falls short of international standards,
particularly in areas such as data exclusivity and pipeline
protection. Counterfeiting is also rife, severely impacting sales
for multinational companies. As a result, these are more likely
to raise prices, in order to recoup losses, or economise in other
areas such as R&D.
Key Benefits of Report
Rely On Our Independent 5-Year Forecasts As A Benchmark
to test other views - a key input for successful budgetary and strategic business planning.
Target Business Opportunities & Risks
through our reviews of latest industry trends, regulatory changes, and major deals, projects and investments
Exploit Latest Competitive Intelligence & Company SWOTS
on your competitors and peers through company rankings by sales, market share and ownership structure - includes multinational and national companies.
Additional Information
Scope of Report
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end-2010 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
Generics market (US$bn)/ as % of total market
Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using
historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.Related Reports:
Snapshots South Africa Pharmaceuticals 2009
Snapshots Hungary Pharmaceuticals 2009
Snapshots Venezuela Pharmaceuticals 2009
Snapshots US Pharmaceuticals 2009
Snapshots Poland Pharmaceuticals 2009
Snapshots Spain Pharmaceuticals 2009
Nigeria Pharmaceuticals and Healthcare Report Q1 2010
Poland Pharmaceuticals and Healthcare Report Q1 2010
Thailand Pharmaceuticals and Healthcare Report Q1 2010
Argentina Pharmaceuticals and Healthcare Report Q1 2010
|
(0 items)
